ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Sep 2019
Last Updated on 02 Sep 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for treating adults with blepharospasm or hemifacial spasm.
Botulinum toxin A must be administered by a neurologist trained in movement disorder or a specialist physician who has undergone training to administer botulinum toxin type A to patients with movement disorders.

Subsidy status
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

MAF does not apply to Botox 200 U injection vial, Dysport 300 U and 500 U injection vials and Xeomin 50 U and 100 U injection vials.

 

Botulinum toxin A for blepharospasm or hemifacial spasm (2 Sep 2019) PES Botulinum toxin A for treating blepharospasm or hemifacial spasm (Published 2 Sep 2019)